ARTICLE | Strategy
Cardio reboot
Why Philip Sager thinks better preclinical tools can spur drug development
March 5, 2015 8:00 AM UTC
A two-year-old FDA initiative is progressing toward its goal of replacing clinical QT studies with preclinical assays that do a better job at predicting proarrhythmia side effects. The question is what impact replacing QT will have on early drug development.
To discuss the issue, BioCentury sat down with Philip Sager, a cardiologist and consulting professor of medicine at Stanford University School of Medicine. He also sits on FDA's Cardiovascular and Renal Drugs Advisory Committee and is a consultant for Sager Consulting Experts Inc. ...